China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green light to conduct a clinical study in China for its drug candidate ICP-189, in combination with ArriVent Biopharma Inc.’s furmonertinib, for the treatment of advanced non-small cell lung cancer (NSCLC). The collaboration between InnoCare and ArriVent was agreed upon in July this year.
ICP-189: An SHP2 Allosteric Inhibitor
ICP-189 is an SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor that has demonstrated favorable pharmacokinetics and a long half-life. The drug has also shown a good safety and tolerability profile, making it a promising candidate for further clinical investigation.
Furmonertinib: A Brain-Penetrant EGFR Inhibitor
Furmonertinib is a highly brain-penetrant, broadly active mutation-selective EGFR (epidermal growth factor receptor) inhibitor. It is approved in China for the first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 (L858R) replacement mutation. Furmonertinib is also under global study for patients with EGFR or HER2 mutant advanced or metastatic NSCLC.
Combining Efforts for Advanced NSCLC Treatment
The combination of ICP-189 and furmonertinib aims to leverage the synergistic effects of these two drugs in treating advanced NSCLC. This clinical study represents a significant step in the ongoing efforts to improve treatment options for patients with this aggressive form of lung cancer.-Fineline Info & Tech
